Search Result

Results for "

cardiac+diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (4) Aldose Reductase (2) Angiotensin Receptor (1) Apoptosis (3) Autophagy (2) Caspase (2) Chloride Channel (1) Isotope-Labeled Compounds (3) Mitophagy (2) Myosin (1) Neurokinin Receptor (2) P-glycoprotein (2) Potassium Channel (3) Reference Standards (2) Sodium Channel (1) TRP Channel (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (14) Endocrinology (4) Metabolic Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1392

Esmolol hydrochloride 3 Publications Verification	Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor	Cardiovascular Disease Endocrinology Cancer
Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol hydrochloride attenuates post resuscitation myocardial dysfunction. Esmolol hydrochloride improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-122605

TRPM4-IN-1 CBA	TRP Channel	Cardiovascular Disease Cancer
TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel TRPM4, with an IC₅₀ of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer .

HY-106577

Cibenzoline Cifenline; Ro 22-7796	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-117494

Flumethiazide NSC 44626	Sodium Channel Chloride Channel	Cardiovascular Disease
Flumethiazide (NSC 44626) is an orally active diuretic agent. Flumethiazide has marked diuretic and natruretic effects with significant effects on Sodium, Chloride and water but not on potassium excretion. Flumethiazide can be used for cardiac diseases like essential hypertension research .

HY-B1392A

Esmolol	Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor	Cardiovascular Disease Endocrinology Cancer
Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-119238

CRL-42872	P-glycoprotein	Cardiovascular Disease
CRL-42872 is a potent bioactive compound that is promising for research of cardiac diseases .

HY-P10640

[Sar1,Thr8]-Angiotensin II	Angiotensin Receptor	Cardiovascular Disease
[Sar1,Thr8]-Angiotensin II is a potent angiotensin II antagonist. [Sar1,Thr8]-Angiotensin II does not alter cardiac performance. [Sar1,Thr8]-Angiotensin II might be safe for patients with cardiac disease .

HY-106577R

Cibenzoline (Standard) Cifenline (Standard); Ro 22-7796 (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577S

Cibenzoline-d4 Cifenline-d₄; Ro 22-7796-d₄	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-B1392S

Esmolol-d7 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Esmolol-d₇ hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase) and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-B1392R

Esmolol hydrochloride (Standard)	Reference Standards Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Esmolol hydrochloride (Standard) is the analytical standard of Esmolol hydrochloride (HY-B1392).This product is intended for research and analytical applications. Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-17681

Myosin-IN-5	Myosin	Cardiovascular Disease
Myosin-IN-5 (example 3) is a selective cardiac myosin inhibitor with an IC₅₀ of 1.5 μM. Myosin-IN-5 shows much less effective in inhibiting skeletal myofibril activity (IC₅₀ of 43.4 μM). Myosin-IN-5 can be used for the study of hypertrophic cardiomyopathy (HCM) and cardiac diseases .

HY-106577S1

Cibenzoline-d5 Cifenline-d₅; Ro 22-7796-d₅	Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-136907

(S)-Verapamil (S)-(-)-Verapamil	P-glycoprotein Apoptosis	Cardiovascular Disease Cancer
(S)-Verapamil ((S)-(-)-Verapamil) is an orally active MRP1 (ABCC1) modulator with a K_d value of 113 nM for hamster MRP1. (S)-Verapamil regulates MRP1, promotes MRP1-mediated glutathione efflux and the transport of calcein and leukotriene C4, reverses glutathione-activated MRP1 ATPase activity, and ultimately depletes intracellular glutathione and induces cell death. (S)-Verapamil specifically induces apoptosis in MRP1-overexpressing tumor cells. (S)-Verapamil can be used in research related to cancer, cardiac diseases such as supraventricular arrhythmia, and hypertension .

Cat. No.	Product Name

HY-L118

Sodium Channel Blocker Library	187 compounds
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion. MCE offers a unique collection of 187 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Sodium Channel Blocker Library

187 compounds

Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.

MCE offers a unique collection of 187 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Cat. No.	Product Name	Target	Research Area

HY-P10640

[Sar1,Thr8]-Angiotensin II	Angiotensin Receptor	Cardiovascular Disease
[Sar1,Thr8]-Angiotensin II is a potent angiotensin II antagonist. [Sar1,Thr8]-Angiotensin II does not alter cardiac performance. [Sar1,Thr8]-Angiotensin II might be safe for patients with cardiac disease .

Cat. No.	Product Name

HY-K6303

Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies.

Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit

MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies.

Cat. No.	Product Name	Chemical Structure

HY-106577S

Cibenzoline-d4
Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cibenzoline-d4

Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-B1392S

Esmolol-d7 hydrochloride
Esmolol-d₇ hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase) and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

Esmolol-d7 hydrochloride

Esmolol-d₇ hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase) and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-106577S1

Cibenzoline-d5
Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cibenzoline-d5

Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.